Eiger Biopharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2011
Net Income	-74.96	-96.78	-33.92	-65.05	-70.25	-52.39	-42.45	-47.09	-13.32	-1.52	Upgrade
Depreciation & Amortization	0.75	0.84	0.8	0.65	0.49	0.05	0.04	0.02	0.01	0.01	Upgrade
Share-Based Compensation	5.01	8.32	7.9	5.97	5.68	5.01	4.24	3.19	0.23	0.03	Upgrade
Other Operating Activities	-5.34	4.61	-46.13	-4.75	0.47	4.66	-0.21	5.9	3.95	0.2	Upgrade
Operating Cash Flow	-74.55	-83.01	-71.34	-63.19	-63.61	-42.67	-38.37	-37.97	-9.13	-1.28	Upgrade
Capital Expenditures	-0.23	-0.34	0.06	-0.26	-0.48	-0.14	-0.04	-0.06	-0.05	-0	Upgrade
Acquisitions	0	0	0	0	0	0	0	28.02	0	0	Upgrade
Change in Investments	74.46	9.97	14.98	-44.53	-16	-28.94	22.5	-32.15	0	0	Upgrade
Other Investing Activities	-	-	46.49	-	-	-	0.2	-	-	-	Upgrade
Investing Cash Flow	74.23	9.63	61.53	-44.79	-16.47	-29.09	22.66	-4.19	-0.05	-0	Upgrade
Share Issuance / Repurchase	0.06	71.56	3.3	96.97	53.32	90.74	19.94	50.34	0	0	Upgrade
Debt Issued / Paid	0	5.45	-0.18	0	4.05	9.94	0	14.76	5.98	0	Upgrade
Other Financing Activities	-0.02	-0.05	0.05	0.5	0.83	0.31	0.05	0.04	7.2	1.92	Upgrade
Financing Cash Flow	0.04	76.96	3.17	97.46	58.2	100.98	19.99	65.14	13.18	1.92	Upgrade
Exchange Rate Effect	-0.08	0	0	0	0	0	0	0	0	0	Upgrade
Net Cash Flow	-0.36	3.58	-6.64	-10.51	-21.89	29.23	4.28	22.98	4	0.63	Upgrade
Free Cash Flow	-74.78	-83.35	-71.29	-63.44	-64.09	-42.81	-38.42	-38.03	-9.18	-1.28	Upgrade
Free Cash Flow Margin	-474.11%	-618.14%	-587.10%	-	-	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-50.66	-60.07	-63.00	-67.63	-84.38	-94.20	-132.04	-189.92	-1285.41	-198.56	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).